Literature DB >> 28275170

Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course.

Ji An Hwang1,2, Sunyoung Kim3,2, Kyung-Wook Jo1, Tae Sun Shim4.   

Abstract

Little is known about the long-term natural history of Mycobacterium avium complex lung disease (MAC-LD) in untreated patients with stable course.The aim of this study was to investigate the natural course of untreated stable MAC-LD, with a focus on factors associated with clinical deterioration, spontaneous sputum conversion and prognosis.Of 488 patients diagnosed with MAC-LD between 1998 and 2011, 305 patients (62.5%) showed progressive MAC-LD resulting in treatment initiation within 3 years of diagnosis and 115 patients (23.6%) exhibited stable MAC-LD for at least 3 years with a median follow-up duration of 5.6 years. Patients with stable MAC-LD were more likely to have higher body mass index and less systemic symptoms at initial diagnosis compared with patients with progressive MAC-LD, while positive sputum acid-fast bacilli smear, fibrocavitary type and more extensive disease in radiological findings were more associated with progressive MAC-LD. Of the untreated patients with stable MAC-LD, 51.6% underwent spontaneous sputum conversion, with younger age, higher body mass index and negative sputum acid-fast bacilli smear at initial diagnosis found to be predictors of this occurrence.Advanced age, fibrocavitary type and abnormal pulmonary function were negative prognostic factors for survival in patients with stable MAC-LD.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275170     DOI: 10.1183/13993003.00537-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

1.  Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.

Authors:  Ganghee Chae; Yea Eun Park; Yong Pil Chong; Hyun Joo Lee; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2022-08-11       Impact factor: 5.938

2.  Preliminary Observations of Veterans Without HIV Who Have Mycobacterium avium Complex Pulmonary Disease.

Authors:  Christen L Vagts; Israel Rubinstein
Journal:  Fed Pract       Date:  2022-03-11

3.  Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.

Authors:  Keiji Fujiwara; Koji Furuuchi; Akio Aono; Fumiko Uesugi; Tatsuya Shirai; Keitaro Nakamoto; Takafumi Shimada; Fumi Mochizuki; Yoshiaki Tanaka; Hiroaki Iijima; Takashi Yoshiyama; Yuji Shiraishi; Atsuyuki Kurashima; Ken Ohta; Satoshi Mitarai; Kozo Morimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-01       Impact factor: 3.267

4.  In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease.

Authors:  Yong Pil Chong; Kyung-Wook Jo; Byoung Soo Kwon; Mi-Na Kim; Heungsup Sung; Younsuck Koh; Woo-Sung Kim; Jin-Woo Song; Yeon-Mok Oh; Sang-Do Lee; Sei Won Lee; Jae-Seung Lee; Chae-Man Lim; Chang-Min Choi; Jin-Won Huh; Sang-Bum Hong; Sojung Park; Tae Sun Shim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

5.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

6.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

7.  Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.

Authors:  Ju Mi Lee; Jiyun Park; Steven G Reed; Rhea N Coler; Jung Joo Hong; Lee-Han Kim; Wonsik Lee; Kee Woong Kwon; Sung Jae Shin
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

8.  Neutrophil predominance in bronchoalveolar lavage fluid is associated with disease severity and progression of HRCT findings in pulmonary Mycobacterium avium infection.

Authors:  Takashi Inomata; Satoshi Konno; Katsura Nagai; Masaru Suzuki; Masaharu Nishimura
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

9.  Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide.

Authors:  Jieun Kang; Ye-Jee Kim; Tae Sun Shim; Kyung-Wook Jo
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

10.  Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.

Authors:  Getahun Abate; Jack T Stapleton; Nadine Rouphael; Buddy Creech; Jason E Stout; Hana M El Sahly; Lisa Jackson; Francisco J Leyva; Kay M Tomashek; Melinda Tibbals; Nora Watson; Aaron Miller; Edward Charbek; Joan Siegner; Marcia Sokol-Anderson; Ravi Nayak; Greta Dahlberg; Pat Winokur; Ghina Alaaeddine; Nour Beydoun; Katherine Sokolow; Naomi Prashad Kown; Shanda Phillips; Arthur W Baker; Nicholas Turner; Emmanuel Walter; Elizabeth Guy; Sharon Frey
Journal:  Clin Infect Dis       Date:  2021-04-08       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.